Navigation Links
Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection
Date:12/10/2009

significantly higher than with placebo. RISPERDAL® CONSTA® is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS): NMS, a potentially fatal symptom complex, has been reported with the use of antipsychotic medications, including RISPERDAL® CONSTA®. Clinical manifestations include muscle rigidity, fever, altered mental status and evidence of autonomic instability (see full Prescribing Information). Management should include immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, intensive symptomatic treatment and medical monitoring, and treatment of any concomitant serious medical problems.

Tardive Dyskinesia (TD): TD is a syndrome of potentially irreversible, involuntary, dyskinetic movements that may develop in patients treated with antipsychotic medications. The risk of developing TD and the likelihood that dyskinetic movements will become irreversible are believed to increase with duration of treatment and total cumulative dose. Elderly patients appeared to be at increased risk for TD. Prescribing should be consistent with the need to minimize the risk of TD. The syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.

Hyperglycemia and Diabetes: Hyperglycemia, some cases extreme and associated with ketoacidosis, hyperosmolar coma or death has been reported in patients treated with atypical antipsychotics (APS), including RISPERDAL® CONSTA®. Patients starting treatment with APS who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing.

Hyperprolactinemia: As with other drugs that antagonize dopamine D2 receptors,

RISPERDAL® CONSTA® elevates prolactin levels and the elevation
'/>"/>

SOURCE Janssen(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... The global mHealth market ... by 2020, growing at a CAGR of 47.6% from ... Grand View Research, Inc. Monitoring services is expected to ... to 2020.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) ... incidences of chronic diseases such as cancer, heart ailments, ...
(Date:8/27/2015)... 27, 2015 DURECT Corporation (Nasdaq: DRRX ... at three upcoming healthcare conferences.  , ... present at the Rodman & Renshaw Investment Conference on ... conference is being held at the St. Regis Hotel ... live audio webcast of the presentation will be available ...
(Date:8/27/2015)... India , August 27, 2015 According ... Product (Transfer, Hammock, Toilet, Seating, Universal, Standing, Bariatric ), Material (Nylon, ... - Forecast to 2020", published by MarketsandMarkets, the Medical Lifting Sling ... USD 411.5 Million in 2015, at a CAGR of 11.4 % ... 136 ma rket data T ables and ...
Breaking Medicine Technology:mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5DURECT to Participate in Upcoming Healthcare Conferences 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4
... Pharmaceuticals, Inc. (Nasdaq: ALXA ), today announced that ... warrants to purchase shares of its common stock in an ... sole book-running manager in the offering. The ... no assurance as to whether or when the offering may ...
... Wash., Feb. 16, 2012  SCOLR Pharma, Inc. (OTCQB: SCLR) ... nutritional/vitamin products based on the Company,s patented oral drug delivery ... Eleven class-leading products are now being sold under various ... top retail chains.  Each product has ...
Cached Medicine Technology:Alexza Announces Proposed Public Offering of Common Stock and Warrants 2Alexza Announces Proposed Public Offering of Common Stock and Warrants 3Alexza Announces Proposed Public Offering of Common Stock and Warrants 4SCOLR Pharma, Inc. Launches Cutting Edge Nutritional Products at Major Retailers in 2012 2
(Date:8/29/2015)... ... 29, 2015 , ... The popular television program VOICES IN AMERICA, hosted by ... will be devoting an entire short segment to the subject of diabetes. Diabetes is ... on a daily basis, but recent advancements in medical science may prove to be ...
(Date:8/28/2015)... ... 29, 2015 , ... Rio Salado College joined nine educational institutions ... part of the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models Incubator funded ... Breakthrough Models Incubator hosted by EDUCAUSE and NGLC, which is designed to ...
(Date:8/28/2015)... ... , ... An online provider of CPAP machines, masks, supplies, and accessories, My ... affordable by offering shipping at no cost to you, directly to your door on ... size. My Cpap Store is located in Las Vegas, Nevada. , Sleep apnea is ...
(Date:8/28/2015)... , ... August 28, 2015 , ... The Kentucky State ... are qualified for the position they are applying for, they are unable to pass ... employers are considering altering drug testing policies in order to be able to hire ...
(Date:8/28/2015)... ... 2015 , ... With the goal of furthering music education programs in schools, ... Adams County Fairgrounds in Mendon, IL on May 30th, 2015. Backed once again by ... in the underfunded school districts of Mendon and its neighboring town of Quincy, IL. ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2
... The Jewish Home has named Nitin Nanda, M.D., ... Dr. Nanda will also serve as medical director of ... the Home,s Joyce Eisenberg-Keefer Medical Center on the Grancell ... positions, Dr. Nanda will be responsible for the supervision ...
... of Georgia is part of a large national study ... 10,000 healthy individuals in an effort to pinpoint variations ... samples taken from each group will enable a sophisticated ... convey individual risk for the disease that affects about ...
... Md., April 27 Patients with stone disease could ... University of California, San Francisco suggests that ... may be sufficient to inhibit the development of calcium ... Scientific Meeting of the American Urological Association (AUA). Increased ...
... nurses and doctors utilizing expert Geriatric Doctors, the Assistant Director of ... save the medical industry potentially, $200 Billion annually. , ... ... announces a tremendous saving in lives and medical costs of ...
... 27 Estill Medical Technologies, Inc., the industry leader ... the expansion of its Thermal Angel sales and marketing ... by quickly controlling core body temperature and infection risk. ... In emergency medicine, the golden hour refers to the ...
... drugstore.com , inc. (Nasdaq: DSCM ... and pharmacy products, today announced that they have reached ... sales and use taxes owed by the Company for ... )The Company has paid an aggregate of approximately $1.7 ...
Cached Medicine News:Health News:New Chief of Geriatric Psychiatry and Behavioral Health is Announced 2Health News:MCG participating in national study to identify genetic variants in schizophrenia 2Health News:MCG participating in national study to identify genetic variants in schizophrenia 3Health News:Drinking Diet Soda May Reduce the Risk of Forming Kidney Stones 2Health News:Medical Nurse Training, Inc. Announces New Techniques to Achieve Tremendous Savings of Lives and Medical Costs of Over $200 Billion Annually 2Health News:Thermal Angel Supports Infection Control During the Golden Hour 2Health News:drugstore.com, inc. Resolves New Jersey Sales and Use Tax Case 2
... designed with the proper sensitivity and specificity ... of autoimmune disease. Sera from over 2,000 ... individuals were tested during the development of ... compared the results to reference methods such ...
... functional human C1q coated in the solid phase ... stage, CIC in the diluted patient samples and ... into the C1q coated assay wells. After incubation, ... and a ready to use conjugate (goat anti-human ...
... are formed as a host defense against ... phagocytosis. If not cleared, CIC may be ... CIC are increased in Systemic Lupus Erythematosus ... involved in other autoimmune disorders as well ...
The K-ASSAY® D-Dimer Control set is intended to be used a consistent test sample of known concentration for monitoring the performance of D-Dimer immunoturbidimetric assays....
Medicine Products: